AU709191B2 - Protein tyrosine kinase inhibitors for treating osteoarthritis - Google Patents

Protein tyrosine kinase inhibitors for treating osteoarthritis Download PDF

Info

Publication number
AU709191B2
AU709191B2 AU71074/96A AU7107496A AU709191B2 AU 709191 B2 AU709191 B2 AU 709191B2 AU 71074/96 A AU71074/96 A AU 71074/96A AU 7107496 A AU7107496 A AU 7107496A AU 709191 B2 AU709191 B2 AU 709191B2
Authority
AU
Australia
Prior art keywords
tyrosine kinase
protein tyrosine
kinase inhibitor
inhibitor
tyrphostin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU71074/96A
Other languages
English (en)
Other versions
AU7107496A (en
Inventor
R. Nelson Campbell
Thomas R. Sharpe
George W. Vasios
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OsteoArthritis Sciences Inc
Original Assignee
OsteoArthritis Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OsteoArthritis Sciences Inc filed Critical OsteoArthritis Sciences Inc
Publication of AU7107496A publication Critical patent/AU7107496A/en
Application granted granted Critical
Publication of AU709191B2 publication Critical patent/AU709191B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU71074/96A 1995-09-11 1996-09-11 Protein tyrosine kinase inhibitors for treating osteoarthritis Ceased AU709191B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52629095A 1995-09-11 1995-09-11
US08/526290 1995-09-11
PCT/US1996/014491 WO1997011692A2 (en) 1995-09-11 1996-09-11 Protein tyrosine kinase inhibitors for treating osteoarthritis

Publications (2)

Publication Number Publication Date
AU7107496A AU7107496A (en) 1997-04-17
AU709191B2 true AU709191B2 (en) 1999-08-26

Family

ID=24096728

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71074/96A Ceased AU709191B2 (en) 1995-09-11 1996-09-11 Protein tyrosine kinase inhibitors for treating osteoarthritis

Country Status (8)

Country Link
US (2) US6552066B1 (enExample)
EP (1) EP0850055B1 (enExample)
JP (1) JPH11512708A (enExample)
AT (1) ATE298566T1 (enExample)
AU (1) AU709191B2 (enExample)
CA (1) CA2231509C (enExample)
DE (1) DE69634900T2 (enExample)
WO (1) WO1997011692A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634900T2 (de) * 1995-09-11 2006-05-18 Osteoarthritis Sciences, Inc., Cambridge Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
DE19845372A1 (de) * 1998-10-02 2000-04-20 Gruenenthal Gmbh Verwendung von Katecholderivaten als Proteinaseninhibitoren
JP2002532493A (ja) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー Ｊｎｋプロテインキナーゼ阻害剤としての４−アリールオキシインドール
EP1157019B1 (en) * 1998-12-17 2003-03-19 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
BR9916324A (pt) 1998-12-17 2001-10-02 Hoffmann La Roche 4,5-pirazinoxindóis como inibidores de proteìna quinase
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
WO2000042213A1 (en) 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
US7070936B1 (en) 1999-01-13 2006-07-04 The Research Foundation Of State University Of New York Method for designing protein kinase inhibitors
EP2322226A3 (en) * 1999-07-21 2011-08-17 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
EP1875900A3 (en) * 2000-01-24 2010-07-21 Genzyme Corporation JAK/STAT pathway inhibitors and the use thereof for the treatment of osteoarthritis
AU2968701A (en) * 2000-01-24 2001-07-31 Genzyme Corporation Jak/stat pathway inhibitors and the uses thereof
US20030152572A1 (en) * 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
US7067550B2 (en) * 2000-11-03 2006-06-27 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's Disease
EP1341548A4 (en) * 2000-11-03 2006-06-14 Massachusetts Inst Technology METHOD FOR IDENTIFYING TREATMENTS AGAINST NEUROTOXICITY IN ALZHEIMER DISEASE CAUSED BY $ g (b) -AMYLOIDPEPTIDE
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
MXPA04003758A (es) * 2001-10-22 2005-06-20 Univ New York State Res Found Inhibidores de proteina - cinasas y proteina-fosfatasas, metodos para disenarlos y metodos para usarlos.
US7005445B2 (en) * 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
EP1487434B1 (en) * 2002-03-06 2007-05-09 The Medical Research and Education Trust Botanical extract compositions with anti-cancer activity comprising isoliquiritigenin
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
WO2005003765A1 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab Isothermal titration calorimetry assays
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2006007664A1 (en) * 2004-07-22 2006-01-26 Genomics Research Partners Pty Ltd Agents and methods for diagnosing osteoarthritis
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
CN101124228B (zh) 2004-12-14 2011-06-15 阿斯利康(瑞典)有限公司 用作抗肿瘤药物的吡唑并嘧啶化合物
DE102005005274A1 (de) * 2005-02-04 2006-08-10 Peter Heger Verwendung von Hydroxystilben-haltigen Wirkstoffen zur Prävention und Behandlung chronisch-entzündlicher Erkrankungen
US7820683B2 (en) 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
JP5137818B2 (ja) * 2006-03-20 2013-02-06 生化学工業株式会社 関節リウマチの処置剤
US7838542B2 (en) * 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
WO2009026705A1 (en) * 2007-08-24 2009-03-05 The University Of Western Ontario Method of diagnosing and treating osteoarthritis
RS52573B (sr) 2008-02-07 2013-04-30 Boehringer Ingelheim International Gmbh Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
CN101396369B (zh) * 2008-08-07 2010-12-01 杜宁 槐角苷的制药应用
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0446120A (ja) 1990-06-11 1992-02-17 Kyowa Hakko Kogyo Co Ltd 血管新生抑制剤
DE69133281T2 (de) * 1990-07-06 2004-05-06 Gencell S.A. Rezeptoren der wachstumsfaktoren aus fibroblasten
US5262565A (en) * 1990-11-16 1993-11-16 Eisai Co., Ltd. Naphthalene derivatives
EP0580609A1 (en) 1991-03-22 1994-02-02 Xenova Limited Pharmaceutical xanthone derivatives
WO1993005014A1 (en) 1991-09-05 1993-03-18 Pharno-Wedropharm Gmbh Aromatic sulfonamide derivatives, their use as enzyme inhibitors and pharmaceutical compositions containing them
GB2262524A (en) 1991-12-18 1993-06-23 Sandoz Ltd Pharmaceutically active 2-hydroxy-benzylamines
SK280617B6 (sk) 1992-01-16 2000-05-16 Hoechst Aktiengesellschaft Arylcykloalkylové deriváty, spôsob ich prípravy, f
US5565448A (en) 1992-02-24 1996-10-15 Smithkline Beecham Corporation Medicament
WO1993018173A2 (en) 1992-03-11 1993-09-16 Xenova Limited Cd4 binding agents and inhibitors of collagenase and protein kinase c
JPH0725761A (ja) * 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd 軟骨保護剤
US5728868A (en) * 1993-07-15 1998-03-17 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
WO1995005824A1 (en) 1993-08-24 1995-03-02 Smithkline Beecham Corporation Aaptamines and method of use thereof
ATE202571T1 (de) 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
IL107736A (en) * 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
US5591740A (en) 1995-06-07 1997-01-07 Osteoarthritis Sciences, Incorporated Use of debromohymenialdisine for treating osteoarthritis
DE69634900T2 (de) * 1995-09-11 2006-05-18 Osteoarthritis Sciences, Inc., Cambridge Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
FR2753969B1 (fr) * 1996-09-27 1998-10-30 Adir Nouveaux derives de flavones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXPERT OPINION ON INVESTIGATIONAL DRUGS, VOL.4, NO. 3, MARCH 1995, PP.253-256, XP000614075 A.C. HANGLOW ET AL. *
J. IMMUN.,V.152,NO.7,APRIL 1994, PP3637-44,BEI XIE ET AL. *

Also Published As

Publication number Publication date
WO1997011692A2 (en) 1997-04-03
US6552066B1 (en) 2003-04-22
EP0850055A2 (en) 1998-07-01
JPH11512708A (ja) 1999-11-02
AU7107496A (en) 1997-04-17
WO1997011692A3 (en) 1997-07-03
US20030060515A1 (en) 2003-03-27
CA2231509A1 (en) 1997-04-03
DE69634900T2 (de) 2006-05-18
ATE298566T1 (de) 2005-07-15
CA2231509C (en) 2008-07-08
EP0850055B1 (en) 2005-06-29
DE69634900D1 (de) 2005-08-04

Similar Documents

Publication Publication Date Title
AU709191B2 (en) Protein tyrosine kinase inhibitors for treating osteoarthritis
JP7323592B2 (ja) 癌を治療するための併用療法
Blot et al. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage
Chan et al. Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate.
EP0831834B1 (en) Debromohymenialdisine and related compounds for treating osteoarthritis
Case et al. IL-1 regulation of transin/stromelysin transcription in rheumatoid synovial fibroblasts appears to involve two antagonistic transduction pathways, an inhibitory, prostaglandin-dependent pathway mediated by cAMP, and a stimulatory, protein kinase C-dependent pathway.
Chuang et al. Quercetin metabolites inhibit MMP-2 expression in A549 lung cancer cells by PPAR-γ associated mechanisms
EP0666741B1 (en) Dithiocarbamates for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases
US6887853B2 (en) Use of geldanamycin and related compounds for treatment of fibrogenic disorders
Abe et al. Induction of glucosylceramide synthase by synthase inhibitors and ceramide
US20080220056A1 (en) Treatment for liver disease
JP2011511007A (ja) タンパク質ホメオスタシスの機能不全を特徴とする状態を治療するための方法
JP2005527510A (ja) 癌の治療において一酸化窒素模倣体を使用するための製剤および方法
JP2005504111A (ja) 骨髄腫を処置するためのｃ−ｋｉｔ阻害剤の使用
Furuta et al. High molecular weight hyaluronic acid regulates MMP13 expression in chondrocytes via DUSP10/MKP5
Idris et al. Small molecule inhibitors of IκB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy‐induced bone loss in vivo
Corps et al. Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and-13, in human tendon-derived cells
Zang et al. Report dual PPARα/γLigand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines
WO2005034937A1 (en) Composition for treatment of osteoarthritis containing apigenin as chindroregenerative agent
WO2022031969A1 (en) Combination mast cell inhibition
Szászi et al. Glutathione depletion inhibits lipopolysaccharide-induced intercellular adhesion molecule 1 synthesis
Pintus et al. Heparin inhibits phorbol ester-induced ornithine decarboxylase gene expression in endothelial cells
WO2008054786A9 (en) Methods and compositions for inhibiting gsk-3 in glial cell related disorders
He et al. A small molecule significantly inhibits the bcr/abl fusion gene at the mRNA level in human chronic myelogenous leukemia
Kistler Calmodulin antagonists inhibit retinoic acid-induced cartilage degradation in vitro